FDA Wants More Ceftobiprole Data From J&J/Basilea
This article was originally published in The Pink Sheet Daily
Executive Summary
Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.
You may also be interested in...
Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays
In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm
Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays
In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm
J&J/Basilea's Ceftobiprole Faces Another Setback
A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits